Study of molecular mechanisms involved in cardiovascular alterations in Marfan Syndrome to suggest a new pharmacological strategy to improve patient's life expectancy by Lindsay Escofet, James & Universitat Autònoma de Barcelona. Facultat de Biociències
James Lindsay Escofet  1388358 
 
1 
 
 
 
‘STUDY OF MOLECULAR 
MECHANISMS INVOLVED IN 
CARDIOVASCULAR ALTERATIONS IN 
MARFAN SYNDROME TO SUGGEST 
A NEW PHARMACOLOGICAL 
STRATEGY TO IMPROVE PATIENT’S 
LIFE EXPECTANCY’ 
 
BIOMEDICAL SCIENCES 
FINAL DEGREE PROJECT 
 
 
 
 
 
 
 
Name: James Lindsay Escofet 
Tutor: Francesc Jiménez Altayo 
Date: Juny 2018 
James Lindsay Escofet  1388358 
 
2 
 
INDEX 
 
1. Introduction…………………………………………………………….………………………………………p. 3-4 
2. Material and Methods………………………………………………………………………………………..p. 4 
2.1. Objectives……………………………………………………………………………………………………p. 4 
2.2. Bibliographical research………………………………………………………….………….……..p. 4 
3. Genetic background ……………………………………………………………………..……………….p. 4-5 
4. Cardiovascular molecular alterations…………………………………………………………….….p. 5 
4.1.  Phenylephrine contractions…………………………………………………………………….…p. 6 
4.2.  COX -1 and COX-2 implication……………………………………………………………….…p. 6 
4.3.  NO levels in aortic alterations……………………………………………………………………p. 6 
4.4.  Desmosine role in MFS………………………………………………………………………………p. 6 
4.5. Cardiovascular pathologies………………………………………………………………………..p. 6 
4.6.  TGF - β Over expression……………………………………………………………………………p. 7 
4.7. Matrix Metalloproteinase Activity………………………………………………….……….p. 7-8 
5. Current Pharmacological Treatments……………………………………………………………….p. 8 
5.1. Beta-blockers (BB)…………………………………………………………………………….……...p. 8 
5.2. Angiotensin Converting Inhibitors (ACEI)………………………………………….………p. 8 
5.3. Angiotensin-II Receptor Blockers (ARBsII) - Losartan …………………………p. 8-9 
6. Treatment proposal………………………………………………………………………………………p. 9-10 
6.1. Diagnosis and monitoring of MFS…………………………………………………………p. 9-10 
6.1.1. MiR-29b ……………………………………………………………………………………….p. 9-10 
6.2. Pharmacological Treatment approach………………………………………………………p. 10 
6.2.1. Nanoparticles loaded with Batimastat conjugated with antielastin to 
target aortic aneurism sites in MFS………………………………….…………p. 10-11 
7. Conclusions…………………………………………………………………………………………………p. 11-12 
8. Bibliography………………………………………………………………………………….……………p. 12-14 
 
 
 
 
 
James Lindsay Escofet  1388358 
 
3 
 
‘Study of molecular mechanisms involved in 
cardiovascular alterations in Marfan Syndrome to 
suggest a new pharmacological strategy to improve 
patient’s life expectancy’ 
James Lindsay Escofet, Bachelor in Biomedical Sciences, Universitat Autònoma de Barcelona
 
ABSTRACT 
 
 
 
 
 
 
INTRODUCTION 
 
Marfan Syndrome (MFS) is an 
autosomal dominant inherited 
connective tissue disease caused by a 
mutation in Fibrillin gene 1 (Fbn-1) which 
can lead to various skeletal, pulmonary, 
ocular, and cardiovascular system 
disorders (1). High variability has been 
documented, and, interestingly, we can 
even find clinical variation within the 
same family (same genetic background) 
and, theoretically, there is no gender 
differences.  
 
Being able to elaborate a correct 
procedure to diagnose in an effective 
way those people with MFS has always 
concerned clinicians. In order to do so, it 
is really important to know which are 
those characteristics that can confirm 
the MFS diagnostic. According to The 
Berlin Criteria published in 1986 (2), 
MFS was detected just by phenotypic 
features. Later on, a connection 
between MFS and FBN1, a gene that 
codifies for a protein called Fibrillin, was 
discovered (3). Since then, in 1996, 
another diagnosis criteria appeared, the 
Ghent Criteria (Ghent-1), based on a 
revision of the Berlin Criteria but 
including mutations in FBN1 as a  
 
 
 
 
 
 
 
 
 
 
 
 
 
complement for the determination. 
Finally, in 2010, by an update of Ghent-
1, Ghent-Nosology- II was stablished as 
the actual criteria to diagnose Marfan 
Syndrome that included, above all, not 
only mutations in FBN1, but specific 
characteristics such as ectopis lentis 
and aortic dilation (4). 
 
According to the results obtained from a 
study of the Danish population based on  
Ghent Nosology II diagnosis criteria it 
affects 6,5/100.000 people (5). It is 
relevant to mention the importance of 
the moment of diagnostic, considering 
that an early detection, can improve the 
prognostic of the patient, mainly with the 
consequences related to aortic dilation. 
Nowadays, the average age of MFS 
diagnosis is 19 years.  
 
MFS phenotypical characteristics are tall 
and thin people with disproportionately 
long limbs. Furthermore, there are 
specific features such as aortic dilation 
(evaluated through Z-Score), pectus 
excavatum, deteriorated teeth, ectopis 
lentis, positive Steinberg Test, high 
palate, skin striae distensae, 
arachnodactyly, lens dislocation and 
myopia. Life expectancy of MFS patients 
depends of the severity of 
Marfan Syndrome is a connective tissue disease originated by mutations in  the FBN1 
gene. Aortic aneurism is the most severe consequence of this syndrome and the most 
common cause of death in MFS patients. Many factors are altered in the molecular 
mechanisms involved in MFS’s cardiovascular affectations, such as TGF - β, NO, COX-
1, COX-2, MMPs (2 and 9) … Since the cure for MFS remains unknown, a treatment 
based on Nanoparticles loaded with MMP inhibitor and conjugated with elastin ab is 
proposed as new pharmacological strategy to improve patient’s life expectancy. 
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cardiovascular affectation, although it 
has significantly improved over the last 
30 years, thanks to medical and surgical 
advances (6) 
 
MATERIAL AND METHODS 
Objectives 
Firstly, main objectives were stablished 
as a guideline to elaborate the review: 
- Assimilate general characteristics of 
MFS; phenotypic and genotypic. 
 
- Fully understand the different 
affected cardiovascular molecular 
mechanism in MFS 
 
- Research on the current treatment 
for MFS.  
 
- Being aware of the latest clinical 
trials on MFS treatment strategies. 
 
- Suggest a new pharmacological 
strategy to improve patient’s life 
expectancy, considering the 
molecular mechanisms involved in 
MFS. 
Bibliographical research 
To fulfill such objectives several 
databases had to be examined.  
Starting with Pubmed, over 50 articles 
were consulted following strict search 
criteria. Depending on what was 
intended the information being searched 
for, the database was first stablished 
(Gene, Protein, Nucleotide, …). Then, 
release and revision date were set to 
obtain articles published over the last 
decade.  Furthermore, after knowing that 
G. Egea is probably one of the most 
well-known investigators in MFS 
research, search was focused on finding 
his most recent publications on the field. 
Directly from his articles, many 
references were checked and revised to 
obtain more specific information mainly 
about molecular mechanisms involved 
in MFS in different situations. 
To collect information about Fibrillin-1 
protein and other proteins involved in 
MFS pathology, protein databases were 
consulted, Uniprot proving to be the 
most useful.  
Detailed information about FBN-1 gene 
was gathered basically from Ensemble 
and OMIM.  
To get to know which current MFS 
investigation and clinical trials are 
currently taking place, clinicaltrials.org 
was consulted and used to get a clear 
idea about which direction MFS 
treatments are taking.  
Finally, a brief interview took place with 
Dr. Evangelista (Director of the 
Multidisciplinary Unit of MFS in 
Catalunya and Coordinator of the Aortic 
Pathological Unit of Vall d’Hebron 
Hospital) who is a reference in treating 
MFS patients and research.  
GENETIC BACKGROUND  
FBN1 
Gene FIBRILLIN-1; FBN1 
Organism Homo Sapiens 
(Human) 
Location 15q21.1 
Exon count 66 
Size 237483 bp 
Table 1. General information on FBN1. 
Fibrilin-1 is a 330 kDa glycoprotein 
formed by 57-59 domains; 47 EGF-like 
(43 calcium-binding EGF), 8 TGF-β 
binding (TB) and 2 hybrid domains 
(EGF-like + TB) which serves as a 
structural element of calcium-binding 
microfibrils. These microfibrils are 
responsible for structural support to 
elastic and non-elastic connective 
tissues (7). 
Mutations in FBN1 are the genetic basis 
of MFS. FBN1 is a gene that codifies for 
a protein Fibrilin-1. Firstly, it generates a 
preprotein which is processed 
proteolytically to obtain two different 
proteins, one of them is involved in 
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Extracellular Matrix organization and 
deposition (8). 
Once protein Fibrilin-1 has been 
synthetized, it is transported towards the 
extracellular matrix due to its structural 
function. When Fibrilin-1 gets to the EC 
matrix they bind between them to form 
microfibrils. Then, binding of microfibrils 
result in the formation of elastic fibers 
which allow skin, ligaments and blood 
vessels to stretch. These fibers also play 
an important role in supporting functions 
in more rigid tissues, such as bones, 
nerves and the eye’s lens (9). 
In addition, microfibrils are responsible 
for TGF- β regulation by its binding and 
avoiding its interaction with its targets. 
This factor, is involved in growth and 
cellular proliferation control, 
differentiation, motility and even 
apoptosis. Therefore, the 
aforementioned microfibrils have the 
capacity to inactivate this factor by its 
binding, and consequently, activating it 
by its releasement (10). 
In MFS, more than 1300 mutations in 
FBN1 lead to the misfolding of protein 
Fibrilin-1 which can’t function as it is 
supposed to. Most of these pathogenic 
mutations are localized in the cbEGF 
(calcium-binding EGF) domains, 
(Figure 1) involved in the binding of 
calcium which plays an essential 
structural role due to its participation in 
disulphide bonds formation (mediated 
by conserved cysteine residues), intern 
protein interactions restriction and 
proteolysis protection. Then, 
malfunction can be explained by a 
reduction of the number of available 
Fibrilin-1, an alteration in its structure or 
stability of Fibrlin-1, or a problem related 
to its transport to the matrix by ER 
retention. One of the consequences of 
these alterations, is that due to the fact 
of not having enough of functional 
microfibrils, there is an overactivation of 
TGF- β, which can lead to a reduction of 
elasticity, overgrowth and instability of 
tissues (11). 
 
 
Figure 1. Representation of cbEGF13. Cisteine 
residues coloured in yellow (responsible for the 
disulphuric bonds) and N-terminal calcium-bind 
residues coloured in red. (11) 
  
CARDIOVASCULAR MOLECULAR 
ALTERATIONS 
MFS manifest several heart 
abnormalities. The major problem that 
MFS presents is the progressive dilation 
of the ascending aorta which can lead to 
a fatal aortic rupture or dissection. It is 
the most common cause of death in an 
adult MFS patient. Other heart problems 
appear in MFS; mitral valve prolapse, 
mitral valve calcification, Lung Artery 
Dilation, left ventricle hypertrophy (12) 
We must consider that most of the 
studies realized in mice to investigate 
aortic dilation, aneurism and dissection, 
are done in the descending region of the 
aorta instead of the ascendant region 
where most of fatal aneurism take place 
in MFS patients. Ascending Aorta in 
mice is very small and this makes hard 
to experiment with it. This is highly 
important since a recent study (13) 
manifested differences between the 
regions, trying to demonstrate 
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differences in region and gender in 
murine models of MFS Fbn1C1039G/+ 
Phenylephrine contractions 
Regarding region differences, 
phenylephrine induced contractions 
were observed in both regions. 
Phenylephrine has the capacity to 
trigger adrenergic a-1 pathway. 
Interestingly, even though it is commonly 
known that dilation in descending aorta 
is the main cause that can lead to 
aneurism, in the ascending aorta an 
increase in the number of contractions 
takes place instead. This might cause an 
important weakness of the smooth 
muscular cells in the aortic wall. In 
addition, differences in the number of 
contractions were observed between 
gender, observing a larger number of 
contractions in male mice than in female. 
COX -1 and COX-2 implication 
In relation with these phenomena of 
contraction, in the descending aorta, 
seems to be related to a downregulation 
of COX-1 and an upregulation of COX-
2. On the other hand, in the ascending 
aorta, there is an upregulation of COX-2 
in males and a downregulation of COX-
2 expression in females. This means 
that the expression of COX-2 can be 
related to the differences in the number 
of contractions between region and 
gender. Furthermore, COX-2 is 
correlated to a major activation of 
metalloproteinases, and consequently, 
to a major degradation and breaking 
down of elastic fibers. 
NO levels in aortic alterations 
Another factor that was considered in 
this study was nitric oxid (NO). High 
basal levels of NO were observed in 
MFS associated to an aortic alteration. It 
was concluded that high levels of NO, 
regulate negatively contractions induced 
by Phe in both sexes. In females, an 
upregulation of eNOS phosphorylation 
was noticed, probably the main cause of 
NO increase. Furthermore, recent 
studies show that a dysregulation in 
iNOS production plays an important role 
in aortic dilation in MFS. 
Desmosine role in MFS 
Another study focused its attention to the 
role that desmosine played in the aortic 
wall in MFS (14). Results demonstrated 
that the quantity of desmosine didn’t 
differ between MFS mice and WT, 
although that extremely damaged elastic 
network was observed in MFS murine 
models. Another point considered in this 
study, was if FBN1 mutations affected 
the physiological cross-linking during 
early stages in elastogenesis or, 
instead, the elastic complex 
fragmentation in later stages. It was 
concluded that mutations in FBN1 didn’t 
modify elastogenesis in early stages but 
it did cause an elastic complex 
fragmentation in later stages. 
Cardiovascular pathologies 
How MFS was related to certain 
cardiovascular pathologies such as 
Mitral valve prolapse (MVP), mitral valve 
calcification, lung artery dilation or 
ascendant aortic dissection and dilation, 
was tested in a recent study (15). 
A higher prevalence of MVP was 
observed in MFS patients, which could 
be helpful to develop another diagnostic 
element. Calcification of the mitral valve 
was quite rare, so it can’t be useful to 
identify MFS cases. A higher dilation of 
the lung artery was seen in MFS models 
and a limit was stablished so that it could 
be used as a characteristic to help 
diagnosticate MFS patients. Finally 
results confirmed that in MFS, the aortic 
wall presents a larger diameter. It is also 
important to mention that; MFS patients 
show a combination of systolic and 
diastolic disfunctions that are not related 
to a cardiac valves pathology. This can 
be caused by a myocardial primary 
contractile disfunction, resulted from an 
alteration of the elastic component, in 
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this case, probably by problems in 
microfibrils organization. 
TGF - β Over expression  
Transforming growth factor – β family is 
involved in the inhibition of several 
essential processes such as 
proliferation of epithelial, endothelial and 
hematopoietic cells, and even can 
stimulate the synthesis of extracellular 
matrix (16). 
When TFG- β is secreted from the cell, it 
is in the context of LLC (Large Latent 
Complex). LLC consists of TGF- β, the 
TGF- β propeptide (LAP) and an LTBP. 
There is a smaller subcomplex called 
Small Latent Complex (SLC) which 
consists of basically LAP and TGF- β. 
(Figure 2).  
In regard of LTBPs 1-4, they are 
secreted multidomain glycoproteins, 
three of which are directly involved in 
TGF- β regulation (17) 
During secretion, mature TFG-β is 
cleaved from its propeptide although 
both proteins remain associated by 
noncovalent interactions. Then, LTBP is 
required for secretion and processing of 
latent TGF-β and it binds to LAP by 
disulfide bonds. At this point, signaling of 
TGF-β is initiated by proteolytic 
cleavage of LTBP, resulting in the 
release of latent TGF- β complex from 
the ECM. Continuously, TGF-β activates 
through LAP dissociation from the 
mature TGF-β Once TGF- β is released, 
it is able to bind to its type II receptor that 
leads to the phosphorylation and 
activation of type I TGF-β receptors. 
Then, this receptor can phosphorylate 
cytoplasmic transcriptional activation 
proteins such as Smad2 and Smad 3, 
which translocate to the nucleus and 
interact with gene expression (16) 
In MFS, FBN1 mutations can result in a 
failure of matrix large latent complex of 
TGF-β sequestration, which increases 
TGF-β signaling and activation.  
The precise mechanism why TGF-β is 
increased in MFS remains unknown. 
Current data is consistent with the model 
which correlates failure of LLC to 
sequestrate TGF-β, but also other 
mechanisms seem to be involved in 
excessive TGF-B activation and 
signaling, such as high levels of selected 
TGF-β activators (MMP-2, MMP-9 and 
thrombospondin-1) and ligands in aortic 
wall (18). 
 
Matrix Metalloproteinase Activity 
High levels of elastolytic Matrix 
Metalloproteinases (MMPs) are found in 
the aorta of MFS patients. It appears to 
be related to the destruction of structural 
elements from the ECM. In addition, 
MMP-2, MMP-3 and MMp-9, are 
involved not only in ECM destruction but 
in the essential second step of the 
release of TGF-β; cleavage of the LAP 
(latency-associated peptide) 
In this study (19) a non-specific MMP 
inhibitor was tested. It was concluded 
that levels of MMP-2 and MMP-9 were 
decreased and delayed aneurysm 
formation and rupture in MFS murine 
model.  
Furthermore, we must consider that 
MMP-2 derives from mesenchymal 
cells, including Smooth Muscle Cells of 
the aortic media. This is relevant due to 
the fact that these cells are responsible 
for synthesis and maintenance of the 
complex macromolecular structure of 
the aorta.  
Figure 2. Schematic representation of TGF- β’s 
Complexes when secreted from the cell. Modified (17) 
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Through the same testing with 
doxycycline (MMP non-specific inhibitor) 
but applied in MFS mice null for MMP-2, 
it was demonstrated that MMP-2 plays a 
specific role in TGF-β signaling and 
aneurysm formation, through its 
involvement in the activation of latent 
TGF-β and the increase of noncanonical 
signaling cascade downstream of TGF- 
β.  
These conclusions open the possibility 
of developing future treatments for MFS 
patients based on the inhibition of MMP-
2.  
CURRENT PHARMACOLOGICAL 
TREATMENTS 
Nowadays, there is no cure for MFS. 
That is why, the aim of pharmacological 
treatment is to slow or stop the 
development of clinical signs (above all, 
aortic dilation to avoid aortic dissection) 
of MFS (20). (Figure 3) 
Beta-blockers (BB) 
Since probably the most relevant 
affectation of MFS is aortic dilation, 
agents which can delay or avoid it, must 
be considered.  
Consequently, B-Blockers have always 
been in the first-line treatment for its 
capacity to reduce blood pressure by 
blocking the effects of epinephrine, and 
therefore, preventing aortic 
complications in MFS (21).  
In summary, oral BB can reduce arterial 
and pulse pressures, submitting the 
aortic wall to less stress by decreasing 
the expulsion force of the left ventricle. 
Despite its benefits, BB therapy has 
recently raised doubts about its efficacy, 
including side-effects and intolerance 
that some patients experienced (20). 
Angiotensin Converting Inhibitors 
(ACEI)  
ACEI contribute to reduce arterial 
pressure and conduit arterial stiffness.  
Not only ACEI are involved in lowering 
the blood pressure, but presents other 
effects that can contribute to improve 
MFS conditions such as preventing 
cystic medial degeneration, apoptosis of 
VSMCs, and aortic dissection in rats, by 
inhibiting the activation of Ang-II AT2.  
In general, there are three possible 
mechanisms which could explain the 
overall beneficial effect of ACEIs; 
inhibition of VSMC apoptosis, an 
improvement in the aortic elastic tone 
and the blocking of 
hyperhomocysteinaemia, that results in 
a reduction in MMP activity and a 
vascular stiffness increase (22).  
In order to improve the efficacy of the 
treatment for MFS, there are occasions 
that they can be used in combination 
with BBs.  
Angiotensin-II Receptor Blockers 
(ARBsII) - Losartan (C22H23ClN6O) 
Losartan is a selective and competitive 
Angiotensin type I receptor antagonist. 
Since Angiotensin II acts as a 
vasoconstrictor in vascular smooth 
muscle, blocking this pressor effect 
makes Losartan an antihypertensive 
treatment, promoting vasodilation and 
decreasing aldosterone effects (23). 
Losartan can block Angiotensin II type 1 
Receptor. This receptor plays an 
essential role in MFS pathogenesis. 
Considering the importance of this 
receptor, a study (24) was based on 
applying Losartan in ATR1 -/- mice and 
demonstrated that, firstly, loss of ATR1 
fails to prevent MFS complication, and 
secondly, that Losartan treatment is still 
effective without ATR-1 target, 
suggesting that its therapeutic utility is 
off-target and ATR-1 independent.  
Losartan participates in the inhibition of 
TGF-B expression, becoming important 
as a protective effect. It may be involved 
not only in the process of decreasing 
active TGF- B, but also in TGF-B’s 
noncanonical signaling cascade  
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downstream (19). Interestingly, 
according to a recent study (25) about 
long term-effects of losartan on a MFS 
mouse model, Losartan caused a 
significant improvement in elastic 
organization, ‘breaking stress’ of the 
aortic wall was increased (meaning that 
it made the aortic wall structure more 
resistant) and decreased expression 
and activation of MMP-2 and 9.  
It is also important to mention that 
Losartan was able to increase the active 
force of aortic smooth muscular cells at 
the 6th and 9th month.  
On the other hand, even that endothelial 
dependent relaxation induced by Ach 
was improved by 30% for 3 months, 
however this improvement ends up by 
disappearing accompanied with an 
endothelial NOS reduction too.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therefore, although it offers great 
advantages in a short term, when 
Losartan is consumed for a long period 
of time, beneficial effects of Losartan are 
significantly diminished. 
TREATMENT PROPOSAL 
Diagnosis and monitoring of MFS 
MiR-29b  
In a study with Fbn1C1039G/+ mice, they 
found out higher levels of available TFG-
β (26). This fact can lead to an NF Kappa 
B inhibition, due to the impossibility of 
phosphorylating IKKs complexes which 
also results in an inhibition of IK-Ba 
phosphorylation (Pest is blocked by NF-
KB forming a dimer, kidnapping this 
factor), and, therefore, since NF-kB 
inhibits miR-29b gene expression, low 
levels of activated NF-kB mean high 
levels of miR-29b gene. This mRna is 
Figure 3. Renin-Angiotensin-Aldosterone system and blocking therapeutic 
effect of ARBs and ACEIs. Modified (29) 
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involved in the regulation of Bcl-2 family 
and ECM deposition process. 
ADVANTAGES DISADVANTAGES 
Liquid biopsy – 
Less invasive 
method 
Unspecific – not 
always is MFS 
Early diagnose 
and monitoring 
tool 
No scientific 
evidence of its utility 
Can prevent 
aortic aneurism 
Need more 
knowledge on 
miRNAs 
Possible future 
treatment 
Unknown side-
effects if inhibited 
 
Table 2. Advantages and disadvantages 
of miR-29b in MFS. 
It is suggested that ECM destruction, 
due to its participation in cellular 
signaling, the decrease of ECM proteins 
may result in Smooth Muscular Aortic 
Cells apoptosis. Dysregulation of these 
elements lead to problems in ECM aortic 
deposition and increases apoptosis.  
Taking into account this information, a 
treatment based on a specific miR-29b 
inhibiting oligonucleotide was applied in 
this study and demonstrated that there is 
a correlation between the restriction of 
miR-29b and reduced levels of 
apoptosis.  
More interestingly, it stopped the early 
aortic formation although it did not 
interfere with the late aortic formation. 
This might indicate that there is an 
aneurism formation miR-29b dependent 
and a non-dependent.  
Although it may seem an interesting 
treatment approach, at the moment 
there is no clinical trials focusing on 
miRNAs for MFS (27). Surprisingly, 
there is another important way to apply 
this miRNA knowledge to MFS; early 
diagnosis. High levels of miR-29b may 
be a key indicator to diagnose and 
monitoring aortic formation in early 
stages of MFS.  
Pharmacological Treatment 
Approach  
ADVANTAGES DISADVANTAGES 
Aortic aneurysm 
site specific 
target 
Does not cure MFS 
(MMPs inhibition) 
Reduced side-
effects (low dose 
required) 
No clinical trials at 
present day 
Scientific 
evidence in rats 
Not tested in MFS 
murine models 
Stopped aortic 
aneurysm 
formation 
 
 
Table 3. Advantages and disadvantages 
of nanoparticles loaded with MMP 
inhibitors conjugated with elastin ab 
treatment  in MFS. 
As stated before, MMPs are found in a 
higher level in MFS model mice than in 
wild-type, and that leads to destruction 
of elements involved in ECM. Therefore, 
a treatment directed to inhibit MMPs 
could be an attractive approach to 
mitigate aortic wall damage. 
Furthermore, there are two specific 
MMPs (-2 and – 9) that, as mentioned 
before, are also involved in TGF-B 
signaling and activation, and inhibiting 
them has been shown that offers 
significant beneficial effects in aortic 
complications in MFS.   
In recent studies, the effect of systemic 
treatments of MMP inhibitors have 
shown promising results as it decreased 
and delayed aortic aneurysm formation 
in MFS murine model. The problem 
appears when trying to translate this 
results to clinical practice; considerable 
side-effects due to systemic affectation 
or, on the other hand, doses used were 
too low.  
That is why, a directed therapy based on 
targeted nanoparticles (NPs) loaded 
with low doses of MMP Inhibitor was 
proposed. This way, side-effects and 
doses related problems would be solved 
by targeting directly to the site of an 
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aneurysm in the abdominal aorta 
through elastin antibodies. 
In this study (28), intravenous injections 
of nanoparticles loaded with Batimastat 
(MMP Inhibitor) conjugated with elastin 
antibodies, were delivered in rats. 
Results showed that the targeted 
therapy achieved activity MMP 
inhibition, stopped elastin degradation, 
calcification and aortic aneurysmal 
formation at a low dose of BB-94. 
To confirm the beneficial effect of NPs 
therapy in relation to systemic 
administration, same dose administered 
before in NPs, was delivered 
systemically and it was concluded that it 
was ineffective to inhibit MMPs.  
We must consider the fact that these 
conclusions were obtained from non-
MFS mice rats.  
So, knowing that the aim of MFS 
treatment is to delay or stop aortic 
aneurysm formation and aortic wall 
degradation, applying nanoparticles 
loaded with MMP inhibitors (specially 
MMP-2 and -9) and conjugated with 
elastin antibodies to target the aneurysm 
site, in MFS patients appears to be an 
interesting treatment approach. 
CONCLUSIONS 
We have just started to deeply 
understand the mechanisms involved in 
MFS. Not many years ago, MFS used to 
be diagnosed by phenotypical 
characteristics, which, nowadays, has 
radically been substituted by genetic 
evidence; FBN1 mutations.   
As already mentioned before, MFS can 
be caused by more than a thousand 
point mutations in the FBN1 gene that 
lead to a misfunction of the Fibrilin-1 
protein. Therefore, it must be taken into 
consideration that there is more than 
one mutation that can cause MFS and 
this fact is a problem when trying to do 
research on this syndrome and 
obtaining specific results of each case 
since representing all possible 
mutations is not viable (studies are 
usually based on murine models with 
one specific knockdown).  
That is why, describing MFS phenotype 
has not been a problem since it is 
already well-stablished but where more 
differences seem to appear and most 
discussion is centered, is concerning the 
molecular mechanisms involved in this 
syndrome. While some affected 
elements are already widely known, 
such as microfibers anomalies and TGF-
β upregulation (although the exact 
pathogenic mechanism still remains 
unknown), recent studies suggest that 
there are many other relevant elements 
dysregulated in this syndrome; NO, 
MMPs, COX-2, … Most studies focus on 
the most severe consequence of MFS; 
aortic aneurysm.  
That is the main reason why treatments 
are mainly focused on preventing that 
condition. Since the understanding of 
MFS basis has just started, 
pharmacological approaches are still 
mainly palliative (Losartán, Verapamil, 
Atenolol, …), which do not solve original 
MFS disorders.  
That explains why, for now, treatment of 
MFS should be based on individual 
features and characteristics to solve 
symptoms in a personalized way. 
Always being aware of aortic wall 
changes (dilation) to administrate BB, 
ARB (II) to prevent further complications. 
Furthermore, when excessive aortic 
dilation takes place, the Gold Standard 
technique remains as the aortic 
prothesis implementation.  
So, therefore, close monitorization of 
patient’s evolution is key to prevent 
further aortic complications. A possible 
way to obtain information of the 
development of the syndrome in an 
easy, economical and painless method, 
is by detecting specific miRNAs (over or 
under expressed in MFS; MiR-29b by 
liquid biopsy which will give us 
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information about the early formation of 
an aortic aneurysm.  
Regarding new pharmacological 
strategies, they should be based on the 
most recent publications since 
knowledge in MFS is increasing year per 
year. Yet, considering that there are 
molecular mechanisms that are involved 
in MFS but are not yet completely 
understood, elaborating a 
pharmacological solution which 
depends on unknown molecular factors, 
is a major obstacle that must be solved.  
Even though all the aforementioned 
drawbacks when trying to suggest a new 
pharmacological treatment, inhibiting 
MMPs can be an attractive alternative 
treatment strategy. To avoid causing 
excessive side-effects and being able to 
obtain better therapeutic response with 
less dose, treatment based on NPs 
loaded with Batimastat and conjugated 
with elastin antibodies, could be an 
effective and interesting approach to 
improve quality and life expectancy in 
MFS patients. Of course, more research 
using MFS murine models needs to be 
done.  
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